Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Profile of antiretroviral agents use in Colombia / Perfil de utilización de antirretrovirales en Colombia

Machado Alba, Jorge E; Atehortúa Otero, Miguel A; Cortés Mejía, Diego A.
Biomédica (Bogotá); 38(4): 527-533, oct.-dic. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-983963


Since the beginning of the epidemic, human immunodeficiency virus (HIV) has taken more than 36 million lives.


To determine the antiretroviral drug prescription patterns in a population of individuals with HIV infection in Colombia. Materials and


Cross-sectional study analyzing the profiles of patients treated with antiretroviral drugs between April 1st and September 30th, 2015. The sociodemographic, pharmacological, and comorbidity variables were identified. Individuals with a positive diagnosis of HIV of all ages and both genders were included.


We found 641 patients with a mean age of 39.0±17 years who were predominantly male (60.2%). The most used medications were lamivudine-zidovudine (51.6%), lopinavir-ritonavir (36%) and efavirenz (24.5%). The combination of lamivudine-zidovudine plus lopinavir-ritonavir was the most prescribed regimen (29.5%), but a total of 80 different regimens was identified. Being an adult between the ages of 45-64 years (OR=2.25; 95%CI 1.367-3.713) was associated with a greater probability of receiving 4 or more antiretrovirals. A total of 267 (41.6%) patients used at least one comedication (range 1-18 drugs), especially anti-ulcer (57.3%), lipid-lowering (28.8%) and anti-hypertensive (28.5%) drugs.


Patients undergoing antiretroviral treatment are receiving medications with elevated intrinsic values at the recommended doses and present comorbidities associated with chronic agerelated conditions. However, these patients receive a great variety of regimens that are not included in the clinical practice guidelines.
Biblioteca responsável: CO42.1
Selo DaSilva